Tracking leftover cancer cells to catch recurrence early
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if a special blood test (called minimal residual disease testing) can find leftover cancer cells early in people with endometrial or cervical cancer. The goal is to see if this test can detect a return of cancer sooner than standard scans or exams.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with endometrial or cervical cancer (confirmed by a biopsy).
- You are about to start or have finished standard treatment (surgery, chemo, radiation, or a combination).
- You are willing to give blood samples for this special test.
- You have not had another cancer that needed treatment in the last 5 years.
- You do not have an active infection or a bleeding problem that would make blood draws unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether DNA found in blood and urine can help detect cervical cancer and monitor it after treatment. If you’re newly diagnosed, these minimally invasive samples may help doctors follow your disease more easily over time.
This trial uses a blood test to find early signs of cancer or leftover tumor cells after treatment. It may help people with certain cancers or those with non-cancerous growths understand their condition better.
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
This study is for women with advanced ovarian cancer who have finished first treatment and are in complete remission. It uses a blood test to look for tiny amounts of leftover cancer cells, which could help guide future care.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Hear when a new Uterine Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.